Q-omics provides the consensus-scored DEFB4B profile across patient tissues and cancer cell-line models. DEFB4B expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, DEFB4B is differentially expressed in 2, with the highest sampling consensus in UCEC. Additionally, DEFB4B RNA expression shows 2,843 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight UCS, and UCEC as cancer lineages where DEFB4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB4B survival associations across molecular data types. DEFB4B RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB4B RNA expression–survival associations across cancer types. High DEFB4B expression shows unfavorable associations in UCS, STAD, KIRC, THYM, LUSC and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for DEFB4B RNA expression.
This table summarizes DEFB4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB4B shows higher tumor expression in UCEC and LUAD. The UCEC box plot shows higher DEFB4B RNA expression in tumor versus normal tissue (log2 FC = +0.263, t-test p = .033).
This table shows molecular features associated with DEFB4B in patient tissues and cancer cell lines. In patient samples, DEFB4B shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and SOFT_TISSUE.
